Announcements Trials
Browse Landscape

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 120Observational 4

Sponsor

Cancer Type

Thoracic 4CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 1Brain Neoplasms 1

Interventions

Blood Specimen Collection 131Surveys and Questionnaires 130Specimen Handling 57Observation 55Radiotherapy 44Interviews as Topic 34Surgical Procedures, Operative 32Drug Therapy 31Biopsy 28Data Collection 26Magnetic Resonance Spectroscopy 25Nivolumab 20Watchful Waiting 20Immune Checkpoint Inhibitors 18Immunotherapy 17Magnetic Resonance Imaging 17Therapeutics 17Standard of Care 16trastuzumab deruxtecan 14Liquid Biopsy 13Tomography, X-Ray Computed 13palbociclib 13Hematologic Tests 12Restraint, Physical 12Focus Groups 11Genetic Testing 11Bevacizumab 10Positron Emission Tomography Computed Tomography 10darolutamide 10enzalutamide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Observational × osimertinib × 1 year × Clear all
NCT06613633 2026-04-29

Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

Fudan University

Completed
4,000 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06538038 2026-03-27

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

PrECOG, LLC.

Recruiting
538 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07491211 2026-03-27

Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases

Fudan University

Active not recruiting
300 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05103605 2025-12-01

POSITHES

AstraZeneca

Active not recruiting
274 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡